-
Callidus Biopharma, Inc., an orphan drug development company, was acquired by Amicus Therapeutics (NASDAQ-FOLD) for $15 Million upfront payment with potential milestone payments totaling $115 million
The undersigned served as the Exclusive Financial Advisor to Callidus Biopharma, Inc. in this transaction.
Walter Greenblatt & Associates
-
WuXi PharmaTech Ltd., (NYSE:WX) the leading provider of contract chemistry services in China, raised $2.2 Million in a Series A Institutional Round of Preferred Equity from a Venture Capital Syndicate including TianDi (New America Partners), UOB Venture Capital and Fidelity BioSciences (Hong Kong)
The undersigned served as the Exclusive Financial Advisor to WuXi PharmaTech in this transaction.
Walter Greenblatt & Associates
-
WuXi PharmaTech Ltd., (NYSE: WX) the leading provider of contract chemistry services in China, raised $19 Million in a Series B Institutional Round of Preferred Equity from a Venture Capital Syndicate including TianDi (New America Partners), UOB Venture Capital and Fidelity BioSciences (Hong Kong)
The undersigned served as the Exclusive Financial Advisor to WuXi PharmaTech in this transaction.
Walter Greenblatt & Associates
-
Advanced BioHealing, Inc., a regenerative medicine company offering engineered tissue products for advanced wound care treatment, raised $2.4 Million in Preferred Equity from Angel Investors
The undersigned served as the Exclusive Financial Advisor to Advanced BioHealing in this transaction.
Walter Greenblatt & Associates
-
Advanced BioHealing, Inc., a regenerative medicine company offering engineered tissue products for advanced wound care treatment, raised $8.0 Million in Preferred Equity from Canaan Partners, Wheatley Partners and other Syndicate Members
The undersigned served as the Exclusive Financial Advisor to Advanced BioHealing in this transaction.
Walter Greenblatt & Associates
-
Advanced BioHealing, Inc., a regenerative medicine company offering engineered tissue products for advanced wound care treatment, acquired from Smith & Nephew the advanced wound care products Dermagraft ® and Transcyte® in an asset purchase.
The undersigned served as the Exclusive Financial Advisor to Advanced BioHealing in this transaction.
Walter Greenblatt & Associates
-
Callidus Biopharma, Inc., an orphan drug development company, raised $4.6 Million in a Series A Institutional Round of Preferred Equity from strategic investors.
The undersigned served as the Exclusive Financial Advisor to Callidus Biopharma, Inc. in this transaction.
Walter Greenblatt & Associates
-
Callidus Biopharma, Inc., an orphan drug development company, raised $1.6 Million in a Series A Institutional Round of Preferred Equity from a strategic investor and Angel investors.
The undersigned served as the Exclusive Financial Advisor to Callidus Biopharma, Inc. in this transaction.
Walter Greenblatt & Associates
-
CytoSorbents, Inc., a critical care immunotherapy company, raised $800,000 in a round of Convertible Debt from Angel investors.
The undersigned served as a Financial Advisor to CytoSorbents, Inc. in this transaction.
Walter Greenblatt & Associates
-
GPB Scientific, LLC, a cell separation company, raised $700,000 in a Series A Round of Preferred Equity from Angel investors.
The undersigned served as the Exclusive Financial Advisor to GPB Scientific, LLC. in this transaction.
Walter Greenblatt & Associates
-
MedAvante, Inc., a service provider to pharmaceutical companies sponsoring clinical trials of therapeutics to treat Central Nervous System disorders, raised $20 Million in a Private Placement of Equity to Goldman Sachs and Trevi Health Ventures
The undersigned served as the Exclusive Financial Advisors to MedAvante in this transaction.
Walter Greenblatt & Associates
-
Core Essence Orthopaedics, a medical device company commercializing best-in-class instruments to enable minimally invasive orthopaedic surgery, has raised $2.9 Million in Convertible Debt from Institutional and Angel Investors.
The undersigned served as the Exclusive Financial Advisor to Core Essence Orthopaedics in this transaction.
Walter Greenblatt & Associates
-
Core Essence Orthopaedics, a medical device company commercializing best-in-class instruments to enable minimally invasive orthopaedic surgery, has raised $5.2 Million in a Series B Institutional Round of Preferred Equity from a from Baird Venture Partners, a subsidiary of R.W. Baird & Co.
The undersigned served as the Exclusive Financial Advisor to Core Essence Orthopaedics in this transaction.
Walter Greenblatt & Associates
-
QuantumBio, Inc., offering next generation drug discovery software, raised $1.1 Million in Convertible Debt from Institutional and Angel Investors
The undersigned served as the Exclusive Financial Advisor to QuantumBio in this transaction
Walter Greenblatt & Associates
-
QuantumBio, Inc., offering next generation drug discovery software, raised $250,000 in Convertible Debt from Ben Franklin Technology Partners
The undersigned served as the Exclusive Financial Advisor to QuantumBio in this transaction
Walter Greenblatt & Associates
-
Pharmacopeia (PCOP-NASDAQ), a leading provider of combinatorial chemistry, computational chemistry tools and other drug discovery services for the pharmaceutical industry, has acquired Oxford Molecular Group (OMG-LSE), a leading provider of computational tools for the pharmaceutical industry including bioinformatics (GCG ?Wisconsin Package), cheminformatics (RS3, DIVA etc.) and molecular modeling tools.
The undersigned served as an advisor to Pharmacopeia in this transaction.
Walter Greenblatt & Associates
-
Pharmacopeia (PCOP-NASDAQ), a leading provider of combinatorial chemistry, computational chemistry tools and other drug discovery services for the pharmaceutical industry, has acquired TMSI, a Japanese Distributor of Software for Computational Chemistry and Molecular Modeling.
The undersigned served as an advisor to Pharmacopeia in this transaction.
Walter Greenblatt & Associates
-
Pharmacopeia (PCOP-NASDAQ), a leading provider of combinatorial chemistry services, computational chemistry tools and other drug discovery services for the pharmaceutical industry, has acquired Synopsys, a technological leader in cheminformatics for drug discovery.
The undersigned served as an advisor to Pharmacopeia in this transaction.
Walter Greenblatt & Associates
-
Pharmacopeia (PCOP-NASDAQ), a leading provider of combinatorial chemistry services, computational chemistry tools and other drug discovery services for the pharmaceutical industry, has acquired Synomics, a provider of middleware software solutions and IT consulting services to enable drug discovery companies to access and integrate biological and chemical data from disparate sources.
The undersigned served as an advisor to Pharmacopeia in this transaction.
Walter Greenblatt & Associates
-
Pharmacopeia (PCOP-NASDAQ), a leading provider of combinatorial chemistry services, computational chemistry tools and other drug discovery services for the pharmaceutical industry, has raised $110 Million in a Private Placement of Public Equity (PIPE)
The undersigned served as an advisor to Pharmacopeia in this transaction.
Walter Greenblatt & Associates
-
Pharmacopeia (ACCL-NASDAQ), a leading provider of combinatorial chemistry services, computational chemistry tools and other drug discovery services for the pharmaceutical industry, has spun- off Pharmacopeia Drug Discovery (PCOP-NASDAQ), a chemistry- based collaborative drug discovery company, focused on the creation of small molecule therapeutics
The undersigned served as an advisor to Pharmacopeia in this transaction.
Walter Greenblatt & Associates
-
Hygeia Therapeutics, a small molecule drug company developing estrogen receptor agonists and androgen antagonists for women?s health and dermatological indications has raised $2.0 Million in Preferred Equity from Angel Investors.
The undersigned served as the Exclusive Financial Advisor to Hygeia Therapeutics in this transaction.
Walter Greenblatt & Associates
-
Azure Therapeutics, a repurposed drug discovery company pursuing development of therapeutics using the 505(b)(2) path, raised a Seed Round of funding from Angel Investors
The undersigned served as the Exclusive Financial Advisor to Azure Therapeutics in this transaction
Walter Greenblatt & Associates
-
PTC Therapeutics, Inc., a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, licensed back rights to a compound it had previously partnered to a collaborator.
The undersigned served as Financial Advisor to PTC Therapeutics in this transaction.
Walter Greenblatt & Associates
-
PTI Holdings, Inc. (PTII-NASDAQ) raised a $25 Million in Senior Debt from PNC Bank.
The undersigned served as an advisor to PTI in this transaction.
Walter Greenblatt & Associates
-
PTI Holdings, Inc. (PTII-NASDAQ) raised $2 Million in Private Equity to Finance an Acquisition Program in Health Care Accessories.
The undersigned served as an advisor to PTI in this transaction.
Walter Greenblatt & Associates
-
PTI Holdings, Inc. (PTII-NASDAQ) raised $8 Million in Subordinated Debt from Brown Brothers Harriman to Finance an Acquisition Program in Health Care Accessories.
The undersigned served as an advisor to PTI in this transaction.
Walter Greenblatt & Associates
-
TotalCat, Inc., offering next generation catalytic devices and recovery and recycling of precious metals from catalytic devices, raised $3.3 Million in Equity from Angel Investors
The undersigned served as a Financial Advisor to Totalcat in this transaction
Walter Greenblatt & Associates
-
FLENTS, a subsidiary of PTI (PTII- NASDAQ) is a market leader in retail health care accessories. Flents has acquired the Assets and Operations of Karlen Manufacturing, Inc.
The undersigned served as an advisor to Flents and PTI in this transaction.
Walter Greenblatt & Associates
-
Omeros, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, has raised $63 Million in a Series E financing
The undersigned served as a syndicate member with Broadmark Capital on behalf of Omeros in this transaction.
Walter Greenblatt & Associates
-
Lerner Medical Devices, Inc., offering targeted phototherapy devices to treat scalp and small area psoriasis, raised a $7.8 Million in a Series A Round of Equity Financing from Angel Investors
The undersigned served as the Exclusive Financial Advisor to Lerner Medical Devices in this transaction.
Walter Greenblatt & Associates